Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
종목 코드 VCYT
회사 이름Veracyte Inc
상장일Oct 30, 2013
CEOMr. Marc A. Stapley
직원 수824
유형Ordinary Share
회계 연도 종료Oct 30
주소6000 Shoreline Court, Suite 300
도시SOUTH SAN FRANCISCO
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호94080
전화16502436300
웹사이트https://www.veracyte.com/
종목 코드 VCYT
상장일Oct 30, 2013
CEOMr. Marc A. Stapley
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음